Darunavir/ritonavir (400/50 mg) fixed-dose combination
Latest DRV/r (400/50 mg) Resources
Darunavir (DRV) is a best in class protease inhibitor commonly used in high-income markets, and has recently been prequalified by the WHO as a fixed-dose-combination with ritonavir (RTV) at a price of US $17.50/pack (EXW) for use in second-line in low- and middle-income countries. CHAI is pleased to share a set of resources to support national decision-making and implementation of this optimal product. Please contact email@example.com with any questions about the resources listed here.
Product Adoption Resources
CHAI's DRV/r resources help countries plan for DRV/r (400/50 mg) introduction and transition.
Tools and resources to support management and coordination of product phase-in as rollout activities take place at the facility level.
Pricing, Quantification, and Monitoring Resources
Tools, guidance, and resources to support countries with budgeting, conducting quantification and supply planning, and monitoring uptake.
Press & Announcements
Announcements, press releases, and articles related to updates on DRV/r.